NTLA Intellia Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

NTLA [NASD]

Intellia Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	0.90%	Shs Outstand	53.37M	Perf Week	-4.94%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-3.16	Insider Trans	-10.68%	Shs Float	48.93M	Perf Month	4.03%
Income	-116.10M	PEG	-	EPS next Q	-0.59	Inst Own	83.20%	Short Float	24.40%	Perf Quarter	19.54%
Sales	50.70M	P/S	25.28	EPS this Y	-6.30%	Inst Trans	0.20%	Short Ratio	13.79	Perf Half Y	65.42%
Book/sh	6.59	P/B	3.56	EPS next Y	-26.40%	ROA	-31.20%	Target Price	31.04	Perf Year	109.73%
Cash/sh	8.01	P/C	2.93	EPS next 5Y	30.00%	ROE	-40.60%	52W Range	9.18 - 27.07	Perf YTD	60.12%
Dividend	-	P/FCF	-	EPS past 5Y	-50.60%	ROI	-	52W High	-8.90%	Beta	1.73
Dividend %	-	Quick Ratio	7.50	Sales past 5Y	-	Gross Margin	-	52W Low	168.63%	ATR	1.97
Employees	270	Current Ratio	7.50	Sales Q/Q	46.80%	Oper. Margin	-	RSI (14)	55.52	Volatility	8.19% 8.67%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-8.30%	Profit Margin	-	Rel Volume	0.49	Prev Close	23.49
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 06 BMO	Payout	-	Avg Volume	865.79K	Price	24.66
Recom	2.10	SMA20	8.22%	SMA50	14.44%	SMA200	39.61%	Volume	296,813	Change	4.98%

Oct-14-20

Initiated

Wells Fargo

Overweight

Sep-18-20

Initiated

Goldman

Buy

$33

Feb-28-20

Upgrade

Oppenheimer

Perform → Outperform

Feb-14-20

Downgrade

Wedbush

Outperform → Neutral

$16

Nov-01-19

Upgrade

Raymond James

Mkt Perform → Outperform

Jul-09-19

Initiated

Robert W. Baird

Outperform

$23

Jun-10-19

Initiated

ROTH Capital

Neutral

$16

May-03-19

Upgrade

Wedbush

Neutral → Outperform

$20 → $21

Apr-12-19

Initiated

Evercore ISI

Outperform

Nov-02-18

Downgrade

Wedbush

Outperform → Neutral

$36 → $20

Oct-29-18

Initiated

Credit Suisse

Neutral

$24

Sep-21-18

Initiated

Raymond James

Mkt Perform

May-15-18

Upgrade

Chardan Capital Markets

Neutral → Buy

$20 → $57.50

Mar-08-18

Initiated

JMP Securities

Mkt Outperform

$76

Nov-01-17

Reiterated

Jefferies

Buy

$36 → $42

Jun-22-17

Resumed

Jefferies

Buy

$36

Mar-28-17

Initiated

Chardan Capital Markets

Buy

$19

Aug-05-16

Upgrade

Jefferies

Hold → Buy

May-31-16

Initiated

Wedbush

Outperform

$38

May-31-16

Initiated

Leerink Partners

Mkt Perform

Oct-19-20 07:30AM	Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) GlobeNewswire
Oct-07-20 04:20PM	Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology GlobeNewswire +13.18%
10:04AM	Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks Barrons.com
Oct-05-20 07:30AM	Intellia Therapeutics Names John F. Crowley to Board of Directors GlobeNewswire +10.30%
Sep-29-20 08:20AM	Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment GlobeNewswire
Sep-28-20 08:00AM	Intellia Therapeutics to Present at Chardans Virtual 4th Annual Genetic Medicines Conference GlobeNewswire
Sep-22-20 09:43AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks
Sep-18-20 09:31AM	Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga
Sep-02-20 08:00AM	Intellia Therapeutics to Present at Bairds 2020 Virtual Global Healthcare Conference GlobeNewswire
Aug-11-20 11:10AM	We're Not Worried About Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Simply Wall St.
11:06AM	How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own? Simply Wall St.
Aug-06-20 09:15AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM	Intellia Therapeutics Announces Second Quarter 2020 Financial Results GlobeNewswire
Aug-03-20 08:00AM	Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire +8.09%
Jul-30-20 12:33PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q2 Earnings Expected to Decline Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates GlobeNewswire
Jul-25-20 11:52AM	Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases. Barrons.com
Jul-14-20 07:07AM	Is Intellia Therapeutics Stock a Buy? Motley Fool
Jul-05-20 10:52PM	Intellia Therapeutics, Inc. (NTLA): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Jul-02-20 11:32AM	Better Buy: Editas Medicine vs. Intellia Motley Fool
Jun-10-20 11:48PM	Edited Transcript of NTLA earnings conference call or presentation 7-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-05-20 04:01PM	Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
12:37AM	Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2% Zacks
Jun-03-20 09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More Zacks +10.22%
07:54AM	Better Buy: CRISPR Therapeutics vs. Intellia Motley Fool
07:02AM	Why Editas Medicine Is Now the CRISPR Stock to Really Watch Motley Fool
Jun-02-20 09:00PM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
11:09AM	Regeneron Expands Deal With Intellia for Hemophilia Treatments Zacks
09:15AM	Stocks Still Rising to Begin June Zacks
07:45AM	The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs Benzinga
02:35AM	Regeneron, Intellia Expand Partnership To Develop Hemophilia Treatments SmarterAnalyst
Jun-01-20 04:00PM	Intellia Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +19.47%
11:46AM	Here's Why Intellia Therapeutics Gained as Much as 18.0% Today Motley Fool
07:57AM	Regeneron to expand development deal with Intellia Therapeutics MarketWatch
07:00AM	Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments PR Newswire
May-22-20 07:39AM	Here's Why Editas Could Beat Intellia to a CRISPR Therapy Motley Fool
May-18-20 07:12PM	Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Cancer Treatment Development Investor's Business Daily +5.89%
May-12-20 06:00AM	Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
May-11-20 07:43AM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St. +14.30%
May-09-20 01:31PM	Intellia Therapeutics, Inc. (NTLA) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 09:15AM	Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:38AM	Recap: Intellia Therapeutics Q1 Earnings Benzinga
07:30AM	Intellia Therapeutics Announces First Quarter 2020 Financial Results GlobeNewswire
Apr-30-20 12:34PM	Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings? What You Should Know Zacks -6.00%
07:50AM	Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer GlobeNewswire
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates GlobeNewswire
Apr-28-20 04:30PM	Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire -7.81%
Apr-13-20 12:00PM	How Does Intellia Therapeutics, Inc. (NASDAQ:NTLA) Affect Your Portfolio Volatility? Simply Wall St.
Apr-06-20 06:26PM	Alnylam, Dicerna Join Forces to Take on Arrowhead GuruFocus.com +6.01%
Mar-31-20 07:30AM	FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics GlobeNewswire
Mar-24-20 04:19PM	Edited Transcript of NTLA earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-27-20 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates Zacks -5.57%
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Feb-20-20 10:53AM	Intellia (NTLA) to Report Q4 Earnings: What's in Store? Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update GlobeNewswire
Feb-19-20 12:31PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline Zacks
Feb-12-20 09:33AM	Here's Why We're Not Too Worried About Intellia Therapeutics's (NASDAQ:NTLA) Cash Burn Situation Simply Wall St.
Feb-10-20 07:30AM	Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposias Engineering the Genome Conference GlobeNewswire +9.40%
Feb-07-20 08:54AM	Implied Volatility Surging for Intellia (NTLA) Stock Options Zacks
Jan-17-20 02:09PM	European ruling threatens Broad's CRISPR gene-editing patents American City Business Journals
Jan-09-20 07:30AM	Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones GlobeNewswire
Jan-06-20 11:00PM	Crispr puts first human in-body gene editing to test Financial Times
Dec-30-19 04:07PM	Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison Investor's Business Daily
03:40PM	Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial Yahoo Finance Video
Dec-25-19 11:30AM	Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year? Zacks
Dec-17-19 06:00AM	Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-14-19 09:13PM	Did Hedge Funds Drop The Ball On Intellia Therapeutics, Inc. (NTLA) ? Insider Monkey
Dec-10-19 10:38AM	Did Intellia Therapeutics, Inc. (NASDAQ:NTLA) Insiders Buy Up More Shares? Simply Wall St.
Dec-05-19 03:49AM	Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 09:42AM	Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 01:03AM	Don't Judge a Month by its First Day Zacks
Dec-02-19 06:33AM	Novartis-linked biotech firm raises $56M for new spinouts American City Business Journals
Nov-26-19 08:00AM	Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference GlobeNewswire
Nov-20-19 03:11PM	Edited Transcript of NTLA earnings conference call or presentation 31-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
09:12AM	Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
01:05AM	The NASDAQ Needs No Break Zacks
Nov-19-19 10:46AM	CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals +10.15%
09:40AM	Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag Zacks
Nov-13-19 01:01AM	NASDAQ Hits New Record Despite Slow Session Zacks
Nov-07-19 09:44AM	Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue? Zacks
06:08AM	These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals
Oct-31-19 09:15AM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.07%
07:30AM	Intellia Therapeutics Announces Third Quarter 2019 Financial Results GlobeNewswire
04:30AM	8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 08:34PM	Hedge Funds Have Never Been This Bullish On Intellia Therapeutics, Inc. (NTLA) Insider Monkey
Oct-29-19 04:05PM	Experts Talk Hot Biotech Stocks at Barrons Breakfast Barrons.com
Oct-24-19 08:00AM	Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update GlobeNewswire
07:30AM	Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Oct-23-19 10:33AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline Zacks
Oct-16-19 08:00AM	Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Oct-07-19 06:00AM	New Cambridge biotech Korro aims to develop a reversible form of gene editing American City Business Journals
Sep-30-19 08:00AM	Intellia Therapeutics to Present at October Healthcare Investor Conferences GlobeNewswire
Sep-26-19 04:30PM	Arbitration Decision Affirms Intellia Therapeutics Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology GlobeNewswire -5.01%
Sep-11-19 01:18PM	Introducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Slid 52% In The Last Year Simply Wall St. +5.77%
Aug-06-19 05:43AM	Edited Transcript of NTLA earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-01-19 12:23PM	Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript Motley Fool
08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM	Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update GlobeNewswire
06:16AM	Legal fight over Broad Institute's patent for CRISPR gene editing flares up again American City Business Journals
Jul-31-19 12:41PM	Is Intellia Therapeutics a Buy? Motley Fool

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rivera Jose E	EVP, General Counsel	Oct 15	Option Exercise	6.83	10,000	68,300	46,294	Oct 16 08:58 PM
Rivera Jose E	EVP, General Counsel	Oct 15	Sale	24.20	5,615	135,883	40,679	Oct 16 08:58 PM
LEONARD JOHN M	President and CEO	Oct 07	Option Exercise	6.83	5,000	34,150	472,352	Oct 09 04:14 PM
LEONARD JOHN M	President and CEO	Oct 07	Sale	21.83	5,000	109,150	467,352	Oct 09 04:14 PM
Rivera Jose E	EVP, General Counsel	Sep 15	Option Exercise	6.83	10,000	68,300	41,909	Sep 17 04:55 PM
Rivera Jose E	EVP, General Counsel	Sep 15	Sale	21.04	5,615	118,140	36,294	Sep 17 04:55 PM
LEONARD JOHN M.	President and CEO	Sep 01	Option Exercise	6.83	5,000	34,150	472,352	Sep 03 04:15 PM
LEONARD JOHN M.	President and CEO	Sep 01	Sale	21.83	5,000	109,150	467,352	Sep 03 04:15 PM
Rivera Jose E	EVP, General Counsel	Aug 18	Option Exercise	6.83	10,000	68,300	37,524	Aug 20 04:13 PM
Rivera Jose E	EVP, General Counsel	Aug 18	Sale	21.00	5,615	117,915	31,909	Aug 20 04:13 PM
LEONARD JOHN M.	President and CEO	Aug 06	Option Exercise	6.83	5,000	34,150	472,352	Aug 07 07:29 PM
LEONARD JOHN M.	President and CEO	Aug 06	Sale	21.83	5,000	109,150	467,352	Aug 07 07:29 PM
Rivera Jose E	EVP, General Counsel	Jul 15	Option Exercise	6.83	10,000	68,300	33,139	Jul 17 04:18 PM
Rivera Jose E	EVP, General Counsel	Jul 15	Sale	22.70	5,615	127,461	27,524	Jul 17 04:18 PM
LEONARD JOHN M.	President and CEO	Jul 01	Option Exercise	6.83	5,000	34,150	472,352	Jul 02 04:10 PM
LEONARD JOHN M.	President and CEO	Jul 01	Sale	21.83	5,000	109,150	467,352	Jul 02 04:10 PM
Rivera Jose E	EVP, General Counsel	Jun 16	Option Exercise	6.83	10,000	68,300	27,897	Jun 18 05:00 PM
Rivera Jose E	EVP, General Counsel	Jun 16	Sale	21.00	5,615	117,915	22,282	Jun 18 05:00 PM
LEONARD JOHN M.	President and CEO	Jun 03	Option Exercise	6.83	5,000	34,150	472,352	Jun 05 05:18 PM
LEONARD JOHN M.	President and CEO	Jun 03	Sale	21.83	5,000	109,150	467,352	Jun 05 05:18 PM
Rivera Jose E	EVP, General Counsel	May 26	Option Exercise	6.83	10,000	68,300	285,722	May 28 05:23 PM
Rivera Jose E	EVP, General Counsel	May 26	Sale	21.21	5,615	119,094	280,107	May 28 05:23 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience